

PROVIDER Update



CONTRACTUAL | AUGUST 24, 2018 | UPDATE 18-592 | 3 PAGES

Injectable Medication HCPCS/DOFR Crosswalk Reference Table Updated – 3rd Quarter 2018

On July 17, 2018, the Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The approved updates are effective October 30, 2018, and are listed on pages 2 through 3. The DOFR categories into which injectable medications are placed mirror the DOFR matrix categories located in the *Provider Participation Agreement (PPA)*. The update includes:

- The addition of 13 new medications and their DOFR categories.
- Updates and changes to 13 injectable medication procedure codes.
- One update to the primary DOFR category.

ADDITIONAL INFORMATION

Relevant sections of the provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on the provider website at provider.healthnet.com.

Providers are encouraged to access the provider portal online at provider.healthnet.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact CalViva Health at 1-888-893-1569.

THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

PROVIDER SERVICES

1-888-893-1569
www.healthnet.com

ADDITIONS TO INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from CalViva Health and Health Net participating physician groups (PPGs).

HCPCS Codes*	Brand Name	Generic Name	Primary Category	Secondary Category
C9399, J3490	Akynzeo®	Fosnetupitant and palonosetron for injection, for intravenous injection	Therapeutic injection	Chemo adjunct
C9399, J3590	Andexxa®	Coagulation factor Xa (recombinant), inactivated-zhzo lyophilized powder for reconstitution and intravenous injection	Therapeutic injection	Blood/blood products for hemophilia
C9399	Praxbind®	Idarucizumab injection, for intravenous use	Therapeutic injection	
J3590	Aimovig™	Erenumab-aooe injection, for subcutaneous use	Self-injectable	
J3590	Crysvita®	Burosumab-twza injection, for subcutaneous use	Therapeutic injection	
J3490	Dexycu™	Dexamethasone intraocular suspension	Therapeutic injection	
J3590	Fulphila™	Pegfilgrastim-jmdb	Self-injectable	Chemo adjunct
J3590	Ilumya™	Tildrakizumab-asmn 100 mg/ml injection, for subcutaneous use	Therapeutic injection	
J3590	Palynziq™	Pegvaliase-pqpz injection, for subcutaneous use	Self-injectable	
J3590	Trogarzo™	Ibalizumab-uiyk injection, for intravenous use	Therapeutic injection	
Q5105	Retacrit™	Epoetin alfa-epbx (For anemia)	Self-injectable	Chemo adjunct
Q5106	Retacrit	Epoetin alfa-epbx (For acute kidney injury AKI)	Self-injectable	
Q9993	Zilretta®	Triamcinolone acetate, preservative-free, extended-release, microsphere formulation, 1 mg	Therapeutic injection	

UPDATES/CHANGES TO INJECTABLE MEDICATION PROCEDURE CODES OR MEDICATIONS

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS Codes	Brand Name	Generic Name	Comment
C9032	Luxturna™	Voretigene neparvovec-rzyl	Replaces C9399, J3590
C9462	Baxdela™	Delafloxacin for injection, for intravenous use	Replaces J3490
C9463	Cinvanti®	Aprepitant injectable emulsion, for intravenous use	Replaces J3490
C9464	Varubi®	Rolapitant hcl IV emulsion	Replaces J3490
C9465	Durolane®	Sodium hyaluronic, for single intra-articular injection 60mg/3ml	Replaces J3490
C9466	Fasenra™	Benralizumab, for subcutaneous use	Replaces C9399, J3590
C9467	Rituxan hycela™	Rituximab and hyaluronidase human injection, for subcutaneous use	Replaces C9399, J3590
C9468	Rebinyn®	Coagulation Factor IX (Recombinant), GlycoPEGylated lyophilized powder for solution for intravenous injection	Replaces J7199
Q5103	Inflectra®	Infliximab-dyyb, biosimilar, 10 mg	Replaces Q5102
Q5104	Renflexis™	Infliximab-abda, biosimilar, 10 mg	Replaces Q5102
Q9991	Sublocade™	Buprenorphine extended-release less than or equal to 100 mg	Replaces C9399, J3490
Q9992	Sublocade	Buprenorphine extended-release over 100 mg	Replaces C9399, J3490
Q9995	Hemlibra®	Emicizumab-kxwh injection, for subcutaneous use	Replaces C9399, J3590

CATEGORY UPDATES/CHANGE

Correction to the primary category.

HCPCS Codes	Brand Name	Generic Name	Primary Category	Secondary Category
C9493	Radicava®	Edaravone injection, for intravenous use	Therapeutic injection	Home health/infusion

*HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.